Under construction – not a live service
Sign in
Taking people in United StatesPhase 3

Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia

Key facts

Where
Cleveland, Columbia, Dothan, Great Falls, Houston, Irvine, Las Vegas, Lincoln, Miami, Miami Lakes, Myrtle Beach, Naperville, Nashville, Phoenix, Plano, San Antonio, Snellville, Stockbridge, Winter Park, and Worcester, United StatesSee the 20 sites
Phase
Phase 3

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 2 and 17 years old?

Source: NCT06953869, who can take part

Where in United States

  • Cleveland, OhioHospital not named in the registryContact: Vanda PharmaceuticalsTaking people
  • Columbia, South CarolinaHospital not named in the registryContact: Vanda PharmaceuticalsTaking people
  • Dothan, AlabamaHospital not named in the registryContact: Vanda PharmaceuticalsTaking people
  • Great Falls, MontanaHospital not named in the registryContact: Vanda PharmaceuticalsTaking people
  • Houston, TexasHospital not named in the registryContact: Vanda PharmaceuticalsTaking people
  • Irvine, CaliforniaHospital not named in the registryContact: Vanda PharmaceuticalsTaking people
  • Las Vegas, NevadaHospital not named in the registryContact: Vanda PharmaceuticalsTaking people
  • Lincoln, NebraskaHospital not named in the registryContact: Vanda Pharmaceuticals, Inc.No longer taking part
  • Miami, FloridaHospital not named in the registryContact: Vanda PharmaceuticalsTaking people
  • Miami Lakes, FloridaHospital not named in the registryContact: Vanda PharmaceuticalsTaking people
  • Myrtle Beach, South CarolinaHospital not named in the registryContact: Vanda PharmaceuticalsTaking people
  • Naperville, IllinoisHospital not named in the registryContact: Vanda PharmaceuticalsTaking people
  • Nashville, TennesseeHospital not named in the registryContact: Vanda PharmaceuticalsTaking people
  • Phoenix, ArizonaHospital not named in the registryContact: Vanda PharmaceuticalsTaking people
  • Plano, TexasHospital not named in the registryContact: Vanda PharmaceuticalsTaking people
  • San Antonio, TexasHospital not named in the registryContact: Vanda PharmaceuticalsTaking people
  • Snellville, GeorgiaHospital not named in the registryContact: Vanda PharmaceuticalsTaking people
  • Stockbridge, GeorgiaHospital not named in the registryContact: Vanda PharmaceuticalsTaking people
  • Winter Park, FloridaHospital not named in the registryContact: Vanda PharmaceuticalsTaking people
  • Worcester, MassachusettsHospital not named in the registryContact: Vanda PharmaceuticalsTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Vanda Pharmaceuticals
Trial code
NCT06953869EU 2024-516411-24-00
Record updated
5 June 2026
Original description
This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female pediatric participants with insomnia disorder.Read full original descriptionShow less

A Multicenter, Double-Blind, Randomized Study to Evaluate the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia

This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female pediatric participants with insomnia disorder.

Inclusion: Ability and acceptance to provide written informed consent of the participant or legal guardian (and assent as required); Confirmed clinical diagnosis of insomnia disorder; Males and Females between 2 and 17 years, inclusive; The sleep disturbance must not be a result of another medication.

Exclusion: Inability to dose daily with tasimelteon or previous intolerance to tasimelteon; A positive test for drugs of abuse; Indication of impaired liver function; Pregnant or lactating females.

ClinicalTrials.gov NCT06953869 · EU CTIS 2024-516411-24-00